JRCT ID: jRCT2031240246
Registered date:31/07/2024
Phase I/II basket trial: Boron Neutron Capture Therapy (BNCT) using CICS-1 and SPM-011 for patients with recurrent solid malignant thoracic tumors that are unresectable and perceived challenging to treat with standard treatment
Basic Information
Recruitment status | Pending |
---|---|
Health condition(s) or Problem(s) studied | Thoracic solid malignant tumor |
Date of first enrollment | 31/07/2024 |
Target sample size | 30 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | - Intravenous administration of investigational drug. 1st time/2nd time - Neutron irradiation of the clinical target volume with the investigational device. 1st time /2nd time - Intravenous injection of 18F-FBPA and radiation exposure from PET-CT scan. |
Outcome(s)
Primary Outcome | - Occurrence rate of dose-limiting toxicity - Response rate (RECIST v1.1) |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | <= 85age old |
Gender | Both |
Include criteria | - Written informed consent must be obtained from the subject. - Patients with histopathological diagnosed malignant tumor (except cutaneous angiosarcoma) - Measurable disease, as defined by RECIST v1.1. - Patients diagnosed with recurrent malignant tumors that are unresectable and perceived challenging to treat with standard treatment. - Patients with ECOG performance status score of 0 or 1. - Patients whose longest diameter sum of the lesions to be treated is 15 cm or less. |
Exclude criteria | - Patients with active disease or active double cancers other than target lesions. - Patients with imaging findings that affect imaging evaluation of the tumor, such as ground-glass opacities - Patients who received radiation therapy exceeding 65 Gy as a prior treatment for the target lesion. - Any serious concomitant disease that precludes completion of the study treatment. - Patients with remaining complications of Grade 3 or higher related to prior radiation therapy in the irradiation field. |
Related Information
Primary Sponsor | Hayashi Toshimitsu |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | information Clinical trials |
Address | ORIX Kouraibashi Building, 3-2-7 Kouraibashi, Chuo-ku, Osaka Osaka Japan 541-0043 |
Telephone | +81-647071516 |
sp-chiken@stella-pharma.co.jp | |
Affiliation | Stella Pharma Corporation |
Scientific contact | |
Name | Toshimitsu Hayashi |
Address | ORIX Kouraibashi Building, 3-2-7 Kouraibashi, Chuo-ku, Osaka Osaka Japan 541-0043 |
Telephone | +81-6-4707-1516 |
sp-chiken@stella-pharma.co.jp | |
Affiliation | STELLA PHARMA CORPORATION |